BCL2 and breast carcinoma: For example, lower BCL2 expression is related with poorer clinical outcome in patients with metastatic breast carcinoma in luminal breast cancers [17] and overexpression of the BCL2 gene is found to be associated with resistance against chemotherapeutics treatment [18].